Literature DB >> 2877854

Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.

T Pullar, H A Capell.   

Abstract

Studies of sulphasalazine in rheumatoid arthritis have used largely empirical doses. The available literature suggests that the optimum dose appears to be greater than 40 mg/kg/day. Despite the relationship between dose and efficacy and a good correlation between dose and serum concentrations of sulphasalazine and its metabolites, no relationship has been demonstrated between efficacy and serum concentrations of sulphasalazine or its metabolites, although there is some suggestion that higher concentrations on single dosing are achieved in patients who develop upper gastrointestinal symptoms. Furthermore, acetylator phenotype does not affect efficacy, although upper gastrointestinal symptoms are more common in slow acetylators.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877854     DOI: 10.2165/00003495-198600321-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  19 in total

1.  Salazopyrin in the Treatment of Rheumatoid Arthritis.

Authors:  R J Sinclair; J J Duthie
Journal:  Ann Rheum Dis       Date:  1949-09       Impact factor: 19.103

2.  Salazopyrin in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; E P Butler; R A Crockson; A P Crockson; L Walsh
Journal:  Agents Actions       Date:  1978-06

3.  The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.

Authors:  A K Azad Khan; M Nurazzaman; S C Truelove
Journal:  J Med Genet       Date:  1983-02       Impact factor: 6.318

4.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

5.  Sulfasalazine in severe rheumatoid arthritis: a study to assess potential correlates of efficacy and toxicity.

Authors:  L Martin; D S Sitar; I M Chalmers; T Hunter
Journal:  J Rheumatol       Date:  1985-04       Impact factor: 4.666

6.  Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.

Authors:  T Pullar; J A Hunter; H A Capell
Journal:  Br J Rheumatol       Date:  1985-08

7.  Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.

Authors:  H Schröder; D A Evans
Journal:  Gut       Date:  1972-04       Impact factor: 23.059

8.  Comparison between penicillamine and sulphasalazine in rheumatoid arthritis: Leeds-Birmingham trial.

Authors:  V C Neumann; K A Grindulis; S Hubball; B McConkey; V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

9.  Sulphasalazine in rheumatoid arthritis.

Authors:  B McConkey; R S Amos; S Durham; P J Forster; S Hubball; L Walsh
Journal:  Br Med J       Date:  1980-02-16

10.  The assessment of disease activity in rheumatoid arthritis using a multivariate analysis.

Authors:  R K Mallya; B E Mace
Journal:  Rheumatol Rehabil       Date:  1981-02-01
View more
  3 in total

Review 1.  Pharmacogenetics: implications for therapy in rheumatic diseases.

Authors:  Lesley Davila; Prabha Ranganathan
Journal:  Nat Rev Rheumatol       Date:  2011-08-09       Impact factor: 20.543

2.  Gene polymorphisms and pharmacogenetics in rheumatoid arthritis.

Authors:  Ignacio Rego-Pérez; Mercedes Fernández-Moreno; Francisco J Blanco
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

Review 3.  DMARDs-Gut Microbiota Feedback: Implications in the Response to Therapy.

Authors:  Oscar Zaragoza-García; Natividad Castro-Alarcón; Gloria Pérez-Rubio; Iris Paola Guzmán-Guzmán
Journal:  Biomolecules       Date:  2020-10-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.